Regeneron's Eylea Inflammation Risk Tied to Drug Syringes
- Company to stop selling kits that include affected syringes
- Inflammation rates remain below levels seen in studies
Photographer: Andrew Harrer/Bloomberg
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. said an extensive investigation into a rare and frightening side effect seen in clusters of patients getting its best-selling drug Eylea has been tied to syringes used to inject the medicine into the eye.
The company plans to stop distributing some Eylea kits that contain syringes made from batches that were linked to higher rates of the condition, known as intraocular inflammation.